JP2017524675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524675A5 JP2017524675A5 JP2016573808A JP2016573808A JP2017524675A5 JP 2017524675 A5 JP2017524675 A5 JP 2017524675A5 JP 2016573808 A JP2016573808 A JP 2016573808A JP 2016573808 A JP2016573808 A JP 2016573808A JP 2017524675 A5 JP2017524675 A5 JP 2017524675A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- composition according
- fxii
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 102000000429 Factor XII Human genes 0.000 claims 10
- 108010080865 Factor XII Proteins 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 208000014674 injury Diseases 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 230000008736 traumatic injury Effects 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000001802 infusion Methods 0.000 claims 3
- 208000020431 spinal cord injury Diseases 0.000 claims 3
- 230000009529 traumatic brain injury Effects 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- 102100036774 Afamin Human genes 0.000 claims 1
- 101710149366 Afamin Proteins 0.000 claims 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- 102100029880 Glycodelin Human genes 0.000 claims 1
- 101000585553 Homo sapiens Glycodelin Proteins 0.000 claims 1
- 101000956004 Homo sapiens Vitamin D-binding protein Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 102000051433 human GC Human genes 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14172910 | 2014-06-18 | ||
| EP14172910.3 | 2014-06-18 | ||
| PCT/EP2015/063760 WO2015193457A1 (en) | 2014-06-18 | 2015-06-18 | Therapy using a factor xii inhibitor in a neurotraumatic disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524675A JP2017524675A (ja) | 2017-08-31 |
| JP2017524675A5 true JP2017524675A5 (enExample) | 2018-07-19 |
| JP7109160B2 JP7109160B2 (ja) | 2022-07-29 |
Family
ID=50972542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016573808A Active JP7109160B2 (ja) | 2014-06-18 | 2015-06-18 | 神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20170114119A1 (enExample) |
| EP (1) | EP3157548B1 (enExample) |
| JP (1) | JP7109160B2 (enExample) |
| KR (1) | KR102513050B1 (enExample) |
| CN (1) | CN106456778A (enExample) |
| AU (1) | AU2015276089B2 (enExample) |
| BR (1) | BR112016029624A2 (enExample) |
| CA (1) | CA2950988C (enExample) |
| DK (1) | DK3157548T3 (enExample) |
| ES (1) | ES2886859T3 (enExample) |
| PL (1) | PL3157548T3 (enExample) |
| WO (1) | WO2015193457A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016029624A2 (pt) | 2014-06-18 | 2017-10-24 | Csl Behring Gmbh | terapia usando um inibidor do fator xii em um distúrbio neurotraumático |
| BR112018069868A2 (pt) * | 2016-03-30 | 2019-01-29 | Sinntaxis AB | modulador alostérico negativo do receptor metabotrópico de glutamato 5, usos de um nam, e método de tratamento ou atenuação de dano cerebral maduro |
| KR20230136687A (ko) * | 2016-04-06 | 2023-09-26 | 시에스엘 리미티드 | 죽상동맥경화증의 치료 방법 |
| CN111479587B (zh) | 2017-12-15 | 2024-01-09 | 杰特有限公司 | FXIIa抑制剂在治疗肾纤维化和/或慢性肾脏疾病中的应用 |
| JP7478149B2 (ja) * | 2018-11-28 | 2024-05-02 | オレゴン ヘルス アンド サイエンス ユニバーシティー | 治療用第ｘｉｉ因子抗体 |
| EP4333901A4 (en) * | 2021-05-03 | 2025-07-09 | Harvard College | FC FUSION PROTEIN-BASED THERAPEUTIC AGENT FOR THE TREATMENT OF PANCREATITIS |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
| GB8901859D0 (en) | 1989-01-27 | 1989-03-15 | Shield Diagnostics Limited | Diagnostic test |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| EP0534988A1 (en) | 1990-05-10 | 1993-04-07 | Cetus Corporation | Inhibitors of factor xii activation and applications thereof |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| DE69233069T2 (de) | 1991-03-15 | 2003-11-27 | Amgen Inc., Thousand Oaks | Pegylation von polypeptiden |
| EP0793504B1 (en) | 1994-12-12 | 2005-06-08 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| JP2003530838A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
| US20080108560A1 (en) | 2002-03-05 | 2008-05-08 | Eli Lilly And Company | Heterologous G-Csf Fusion Proteins |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| PT1624891E (pt) | 2003-05-06 | 2010-01-05 | Syntonix Pharmaceuticals Inc | Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia |
| EA008831B1 (ru) | 2003-06-12 | 2007-08-31 | Эли Лилли Энд Компани | Слитые белки аналогов glp-1 |
| WO2005024044A2 (en) | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| WO2005063808A1 (en) | 2003-12-31 | 2005-07-14 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| JP5118492B2 (ja) | 2004-12-23 | 2013-01-16 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 血栓の形成の防止および／または安定化の防止 |
| ES2753183T3 (es) | 2007-02-12 | 2020-04-07 | Csl Behring Gmbh | Aplicación terapéutica de inhibidores de la proteasa de serina de tipo Kazal |
| WO2011069090A1 (en) * | 2009-12-04 | 2011-06-09 | Alavita Pharmaceuticals, Inc. | Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine |
| KR20230116964A (ko) | 2010-12-17 | 2023-08-04 | 셀룰래리티 인코포레이티드 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌손상의 치료 |
| EP2497489A1 (en) * | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| ES2646191T3 (es) | 2011-03-09 | 2017-12-12 | Csl Behring Gmbh | Inhibidores de Factor XII para la administración con procedimientos médicos que comprenden contacto con superficies artificiales |
| EP2548892A1 (en) * | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
| FI2734552T3 (fi) | 2011-07-22 | 2025-02-12 | Csl Behring Gmbh | Monoklonaaliset anti-tekijä xii/xiia -vasta-aineet ja niiden käyttö |
| ES2714999T3 (es) | 2011-09-24 | 2019-05-31 | Csl Behring Gmbh | Terapia de combinación que usa inmunoglobulina e inhibidor de C1 |
| EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| JP6636334B2 (ja) | 2013-03-08 | 2020-01-29 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 遠隔虚血再灌流傷害の治療および予防 |
| US20160166660A1 (en) | 2013-06-28 | 2016-06-16 | Csl Behring Gmbh | Combination therapy using a factor xii inhibitor and a c-1 inhibitor |
| US9587903B2 (en) | 2014-02-24 | 2017-03-07 | Brian E. Sullivan | Pneumatic launcher system and method |
| BR112016029624A2 (pt) | 2014-06-18 | 2017-10-24 | Csl Behring Gmbh | terapia usando um inibidor do fator xii em um distúrbio neurotraumático |
| KR20230136687A (ko) | 2016-04-06 | 2023-09-26 | 시에스엘 리미티드 | 죽상동맥경화증의 치료 방법 |
-
2015
- 2015-06-18 BR BR112016029624A patent/BR112016029624A2/pt not_active Application Discontinuation
- 2015-06-18 PL PL15741128T patent/PL3157548T3/pl unknown
- 2015-06-18 CN CN201580032338.8A patent/CN106456778A/zh active Pending
- 2015-06-18 US US15/318,550 patent/US20170114119A1/en not_active Abandoned
- 2015-06-18 AU AU2015276089A patent/AU2015276089B2/en active Active
- 2015-06-18 DK DK15741128.1T patent/DK3157548T3/da active
- 2015-06-18 WO PCT/EP2015/063760 patent/WO2015193457A1/en not_active Ceased
- 2015-06-18 EP EP15741128.1A patent/EP3157548B1/en active Active
- 2015-06-18 ES ES15741128T patent/ES2886859T3/es active Active
- 2015-06-18 JP JP2016573808A patent/JP7109160B2/ja active Active
- 2015-06-18 CA CA2950988A patent/CA2950988C/en active Active
- 2015-06-18 KR KR1020177001620A patent/KR102513050B1/ko active Active
-
2019
- 2019-10-29 US US16/666,886 patent/US12065481B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023027258A (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| US20230060574A1 (en) | Serum albumin binders | |
| EP3571224B1 (en) | Improved serum albumin binders | |
| JP2024063213A (ja) | 改良された血清アルブミン結合剤 | |
| JP2017524675A5 (enExample) | ||
| JP2020511113A (ja) | 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン | |
| AU2021221287B2 (en) | Engineered anti-IL-2 antibodies | |
| JP2016537340A5 (enExample) | ||
| JP2019513748A5 (enExample) | ||
| JP2020505350A5 (enExample) | ||
| CN108431039A (zh) | 改进的p2x7受体结合剂和包含其的多肽 | |
| TW201828984A (zh) | 使用介白素-17(il-17)拮抗劑治療痤瘡的方法 | |
| JP2026053563A (ja) | 補体関連疾患のための融合タンパク質構築物 | |
| HK40118030A (en) | Improved serum albumin binders | |
| HK40117444A (en) | Improved serum albumin binders | |
| NZ791361B2 (en) | Engineered anti-il-2 antibodies | |
| HK40017968A (en) | Improved serum albumin binders | |
| HK40017968B (en) | Improved serum albumin binders | |
| HK40018516A (en) | Improved serum albumin binders | |
| HK40018516B (en) | Improved serum albumin binders |